U.S. biotech company
Moderna Inc. ( MRNA Quick Quote MRNA - Free Report) focused on drug discovery and development based exclusively on messenger RNA is in every news flash for the past few months due to its engagement in the coronavirus vaccine development. Not only this, clinical trials are showing success of the experimental vaccine. Per the latest news, Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in an ongoing early-stage study. Moderna had conducted two tests in May and will begin phase 3 tests with 30,000 volunteers on Jul 27.
Notable, Moderna shares have gained a whopping 283.6% this year, winning a place on the Nasdaq-100 with its sheer success. Moderna gained more than 4.5% in the key trading session on Jul 14 and added 16.1% after hours.
Currently, Moderna shares are valued at about $28 billion. The inclusion to the index will happen on Jul 20. The dual news of successful clinical trials and index inclusion made the Moderna stock a star performer this week.
More Rally Ahead for Nasdaq-100?
The Nasdaq-100 is home to the most-glamorous stocks of the year. The likes of Apple, Amazon, Tesla, eBay, Netflix and Zoom Video Communications Inc. all have a presence in this highly coveted index. The Nasdaq 100
broke into record territory early last month and has kept on marching northbound. So far this year, the Nasdaq-100 index is up more than 22% while the S&P 500 is down about 0.9%.
If you think that the tech stocks are the most crowded and overvalued bets currently and the Nasdaq-100 may record range-bound trading in the near term, the latest inclusion of Moderna may give you a reason to bet on the Nasdaq-100 ETF. If successful on all clinical trials, Moderna shares are sure to soar in the coming days.
The U.S. government is backing Moderna’s vaccine with about half a billion dollars and has chosen it as one of the first to enter large-scale human trials. A successful vaccine could be a trump card for Moderna, which
never had a licensed product, per Reuters (read: Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress). ETFs in Focus
Against this backdrop, below we highlight a few ETFs that could be tapped on a slew of good news from Moderna.
These ETFs include the likes of
Invesco QQQ ETF ( QQQ Quick Quote QQQ - Free Report) ), First Trust NASDAQ-100 Equal Weighted Index Fund ( QQEW Quick Quote QQEW - Free Report) and ProShares UltraPro QQQ ( TQQQ Quick Quote TQQQ - Free Report) (see all Style Box - Large Cap Growth ETFs here). Moderna-Heavy ETFs
Apart from the Nasdaq-100, Moderna-heavy ETFs like
Renaissance IPO ETF ( IPO Quick Quote IPO - Free Report) , ETFMG Treatments Testing and Advancements ETF ( GERM Quick Quote GERM - Free Report) , Principal Healthcare Innovators Index ETF ( BTEC Quick Quote BTEC - Free Report) and VanEck Vectors Biotech ETF ( BBH Quick Quote BBH - Free Report) should also move higher. All these funds have assets in Moderna in the range of 5.17% to 6.51%. Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>